Munich, Germany, 21 May 2024: Lario Therapeutics CEO Henning Steinhagen and CSO Tom Otis were invited to the inaugural CACNA1E Family Conference to present Lario’s efforts to develop first-in-class CaV2.3 inhibitors for DEE69, a severe neurodevelopmental disorder characterized by de novo gain of function mutation in the CaV2.3 channel encoded by the CACNA1E gene.
Six months ago, CACNA1E International was founded as a parent-led, international organization and is now trying to raise awareness about the CACNA1E-related Developmental Epileptic Encephalopathy Type 69 (DEE69) and encourage development of targeted treatments in the next few years. They are looking for patients who have already been diagnosed, as well as researchers who would like to join their medical and scientific network. All information can be found on their website: cacna1e.org.
Lario Tx was founded in 2021 as a spin-out from Epidarex Exeed (epidarex-exeed.com), the therapeutic discovery engine of Epidarex Capital, with seed investment from Epidarex Capital and Axxam which transferred its participation into Golgi Neurosciences. The Company is rapidly advancing, led by Dr Henning Steinhagen, Co-founder and CEO, together with a highly motivated and experienced team.
For more information about Lario Therapeutics please visit: lariotx.com.